Understanding how the immune system produces antibodies against factor VIII in hemophilia A
Official title: Defining immune pathways involved in the formation of antibodies against factor VIII
Funded at Emory University · NIH-11056177 · Data updated 2026-11-12
This study is looking at how people with hemophilia A respond to a key protein that helps their blood clot, to understand why some develop problems with their treatment while others don’t, and it hopes to find better ways to help those who struggle with their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | March 15, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $117,375 |
| NIH project number | 5R21HL173513-02 |
| Project ID | NIH-11056177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with hemophilia A, especially those who have experienced varying immune responses to factor VIII treatments.
✕Less likely to help
Patients with hemophilia A who do not have any immune response issues related to factor VIII may not benefit from this research.
What this research studies
This research investigates the immune responses of patients with hemophilia A, particularly focusing on how their bodies produce antibodies against factor VIII, a crucial protein for blood clotting. By examining different pathways of B cell activation, the study aims to uncover why some patients develop inhibitors that prevent effective treatment while others do not. The approach includes analyzing B cell responses through advanced sequencing techniques to identify patterns in antibody formation. This knowledge could lead to improved therapies for managing hemophilia A, especially for those who experience complications from current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hemophilia A patients, particularly those who develop inhibitors against factor VIII.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in hemophilia, but this specific approach to B cell pathways is relatively novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Patel, Seema Rajnikant — Emory University
- Study coordinator: Patel, Seema Rajnikant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.